Sanofi CEO Paul Hud­son con­tin­ues hunt for new tech, spear­ing a deal with organoid start­up

Sanofi is dip­ping its toes in­to a wide range of new tech­nolo­gies as CEO Paul Hud­son looks to find its next big break­through. His lat­est pick comes from an emerg­ing field that’s had plen­ty of buzz but few tan­gi­ble re­sults in drug de­vel­op­ment so far.

The French phar­ma an­nounced on Tues­day a deal with Prel­lis Bi­o­log­ics, a new biotech that claims to have de­vel­oped an organoid sys­tem in its labs that can mim­ic the hu­man im­mune sys­tem. Al­though the start­up has on­ly raised a mod­est sum by mod­ern biotech stan­dards — it an­nounced a $14.5 mil­lion Se­ries B in De­cem­ber — its tech­nol­o­gy has at­tract­ed the in­ter­est of large com­pa­nies. In Jan­u­ary, the com­pa­ny al­so an­nounced a li­cens­ing deal with Bris­tol My­ers Squibb.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER